

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drugs In Development, 2021

<https://marketpublishers.com/r/IA09ADDBBA50EN.html>

Date: December 2021

Pages: 77

Price: US\$ 3,500.00 (Single User License)

ID: IA09ADDBBA50EN

Abstracts

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drugs In Development, 2021

SUMMARY

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 12 molecules. The latest report GMDHC3038TDB – Integrin Beta 7 – Drugs In Development, 2021, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) – Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2, 4 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Ulcerative Colitis, Celiac Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammation and Pouchitis.

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut

Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in

Therapeutics Development

Aviara Pharmaceuticals Inc

C4X Discovery Holdings Plc

DiCE Molecules SV Inc

Genentech USA Inc

Gilead Sciences Inc

Morphic Therapeutic Inc

Polpharma Biologics SA

Progenity Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Zealand Pharma AS

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles

etrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-1427 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MORF-057 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PN-943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTG-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha 4 Beta 1 and Alpha 4 Beta 7 for
Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha 4 Beta 7 for Inflammatory Bowel Disease
- Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel
Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-10000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development

Milestones

Featured News & Press Releases

Sep 07, 2021: Protagonist Therapeutics appoints Scott Plevy, M.D., executive vice president and therapeutic head, gastroenterology

Jul 09, 2021: Morphic reports new data from positive phase 1 study of MORF-057, oral integrin inhibitor candidate for IBD

Jul 02, 2021: Morphic Therapeutic to host analyst and investor call on July 9, 2021

May 28, 2021: Morphic Therapeutic to present positive phase 1 data for MORF-057 at ECCO'21 Virtual Congress

Mar 01, 2021: Morphic reports positive interim results from single ascending dose phase 1 clinical trial of MORF-057

Feb 22, 2021: Morphic Therapeutic to host analyst and investor call on March 1, 2021

Jan 19, 2021: Ready-to-use self-injectable formulation of ENTYVIO (vedolizumab) now available for Canadians for the maintenance treatment of moderately to severely active Crohn's disease and ulcerative colitis

Dec 09, 2020: Takeda's pipeline including vedolizumab has potential to contribute significantly to revenue growth over next decade

Oct 13, 2020: Takeda reports positive interim data from trial of Entyvio

Oct 12, 2020: Morphic announces presentation of new data supporting development of MORF-057 at UEG Week Virtual 2020

Sep 23, 2020: Morphic Therapeutic announces first healthy volunteers dosed in Phase 1 clinical trial of MORF-057

Sep 02, 2020: Update on the U.S. Development Program for the investigational subcutaneous formulation of ENTYVIO (vedolizumab) as a maintenance therapy in adults with moderate to severe Ulcerative Colitis

Aug 11, 2020: Roche announces mixed Phase III results of etrolizumab

Jun 23, 2020: Takeda receives U.S. FDA approval to manufacture ENTYVIO (vedolizumab) drug substance at manufacturing facility in Brooklyn Park, Minnesota

May 08, 2020: European commission approves subcutaneous formulation of Entyvio (Vedolizumab) for use as maintenance therapy in adults with moderately to severely active Ulcerative Colitis or Crohn's Disease

Appendix

Methodology

Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Aviara Pharmaceuticals Inc, 2021

Pipeline by C4X Discovery Holdings Plc, 2021

Pipeline by DiCE Molecules SV Inc, 2021

Pipeline by Genentech USA Inc, 2021

Pipeline by Gilead Sciences Inc, 2021

Pipeline by Morphic Therapeutic Inc, 2021

Pipeline by Polpharma Biologics SA, 2021

Pipeline by Progenity Inc, 2021

Pipeline by Protagonist Therapeutics Inc, 2021

Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Pipeline by Zealand Pharma AS, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/IA09ADDBBA50EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IA09ADDBBA50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

